GlobeNewsWire
15 Jun 2026, 16:46 UTC · 2h ago
NMRA INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Neumora Therapeutics, Inc.
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
GlobeNewsWire
15 Jun 2026, 16:46 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Neumora Therapeutics' Phase 3 KOASTAL-2 and -3 studies of navacaprant for major depressive disorder failed to achieve statistical significance on primary or key secondary endpoints. — Clinical trial failure for a lead asset in a major indication typically leads to a severe loss of valuation for biotech companies.
-0.90Neumora Therapeutics is discontinuing the development of navacaprant and reducing its workforce by approximately 35%. — The abandonment of the drug and significant layoffs signal a major strategic setback and a loss of operational scale.
-0.70Holzer & Holzer, LLC is investigating whether Neumora Therapeutics complied with federal securities laws following the stock price drop. — While common after a crash, a securities investigation introduces potential legal liabilities and further investor uncertainty.
-0.30Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
The company failed Phase 3 clinical trials, is discontinuing a drug candidate, and reducing its workforce by 35%.
A shareholder class action lawsuit has been filed alleging that the company made false statements.
The company is under investigation by a securities litigation law firm regarding compliance with federal securities laws.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
47m ago
